Ketoglutaric Acid for Hair Regrowth
Evidence Review created on 11/12/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Alpha-Ketoglutaric Acid, α-Ketoglutaric Acid, Alpha-Ketoglutarate, α-Ketoglutarate, AKG, α-KG, 2-Oxoglutaric Acid, 2-Oxoglutarate, Calcium Alpha-Ketoglutarate, Ca-AKG
Motivation
Ketoglutaric acid (alpha-ketoglutarate) is a small molecule the body makes every day as part of the chemical cycle that turns food into energy. It is sold as a dietary supplement, most often bound to calcium, and appears in some hair serums. Its link to hair comes from the cell’s recycling process, which researchers have studied as a way to restart growth in resting hair roots.
The compound first drew attention from people interested in longevity through lifespan studies in worms and mice. A university laboratory studying that recycling process then applied it to the skin of mice whose hair roots were in a resting state, and this work brought the compound into hair-loss discussions, patent filings and the marketing of supplements and serums.
This review examines the evidence for and against using ketoglutaric acid, taken by mouth or applied to the scalp, to regrow hair. It covers how the compound may act, what animal and human studies have measured, its side effects and drug interactions, the doses used so far, and the measures available to track response.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Primary research, expert commentary and an institutional summary on ketoglutaric acid, its autophagy mechanism and its effects on hair in animals.
-
Stimulation of Hair Growth by Small Molecules that Activate Autophagy - Chai et al., 2019
The primary hair study: topical α-ketoglutarate (α-KG) moved resting (telogen) mouse hair follicles into active growth (anagen) via autophagy (cellular self-recycling); co-authors are named inventors on a hair-growth patent application.
-
Alpha-Ketoglutarate: Benefits and Side Effects - Steve Hill
Explains the shared mechanism: α-KG inhibits ATP synthase (the mitochondrial enzyme that makes cellular energy), lowering TOR (a nutrient-sensing growth regulator) activity and raising autophagy, the pathway linked to hair regrowth in mice.
-
A metabolite produced by the body increases lifespan and dramatically compresses late-life morbidity in mice - Buck Institute
Release on the 2020 calcium alpha-ketoglutarate (Ca-AKG) mouse study reporting improved fur color and coat condition in treated females; the study was partly funded by Ponce de Leon Health, in which several authors held shares.
Only three items qualified. FoundMyFitness (Rhonda Patrick) offers a reposted abstract of the Chai study’s preprint, a 2026 FoundMyFitness Science Digest item on a delayed-release alpha-ketoglutarate (AKG) supplement survey and a brief remark in a members-only FoundMyFitness Q&A #30, none discussing AKG or hair in depth. The Peter Attia episode #357 with Brian Kennedy, who sits on the board of Ca-AKG maker Ponce de Leon Health, covers AKG for healthspan in aging only in a brief segment and does not discuss hair. No directly relevant content on ketoglutaric acid was found from Andrew Huberman (the Huberman Lab hair-loss episode and site search do not cover it), Chris Kresser (site search returned only an unrelated methylation article) or Life Extension Magazine (its archive covers ornithine α-ketoglutarate for wound healing and growth hormone, and a 1998 Life Extension Mix article mentions alpha-ketoglutarate only briefly as an anti-glycation nutrient against cataract formation).
Grokipedia
Reference article on the compound’s chemistry, its role in the citric acid cycle (the cell’s main energy-producing cycle), its epigenetic (gene-switching) cofactor functions and its supplement uses; its focus is biochemistry rather than hair.
Examine
Evidence summary of AKG for muscle protein synthesis, recovery from surgery or trauma and longevity, with dosing and side-effect notes, including adverse effects reported for the arginine salt.
ConsumerLab
Does AKG Extend Lifespan and Slow Aging?
Tod Cooperman’s June 2026 answer concludes that good clinical evidence of AKG or Ca-AKG extending human lifespan or healthspan is lacking and names Ca-AKG sellers; product comparisons are members-only.
Systematic Reviews
Systematic reviews of ketoglutaric acid salts in human recovery and kidney settings, including one on the principal risk; no systematic review or meta-analysis addresses hair outcomes, so the claimed hair effect is unrepresented.
-
Metabolic and Immunomodulatory Effects of α-Ketoglutarate in Burn Injuries: A Systematic Review - Niederegger et al., 2026
Fifteen clinical, animal and mechanistic studies: ornithine α-ketoglutarate improved nitrogen balance (net protein retention) and wound closure after burns; cohorts were small and heterogeneous.
-
Nutritional interventions in patients with burn injury: an umbrella review of systematic reviews and meta-analyses of randomised clinical trials - Naeini et al., 2024
Pooled meta-analyses found no significant effect of ornithine α-ketoglutarate on burn mortality or other clinical outcomes, contrasting with the narrower review above.
-
Nutritional interventions for preventing and treating pressure ulcers - Langer et al., 2024
Cochrane review rating the evidence for ornithine α-ketoglutarate in pressure-ulcer healing as very low certainty, based on one or two trials.
-
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD) - Natale et al., 2025
Cochrane review including two calcium ketoglutarate dialysis trials; in one, 5 of 17 participants withdrew within 1–2 weeks for gastrointestinal intolerance.
Mechanism of Action
AKG is a citric acid cycle intermediate and a source of glutamate and glutamine (Lifespan.io summary).
- Energy-sensing route: In worms and cultured mammalian cells, α-KG binds and partly inhibits ATP synthase, lowering cellular energy and TOR activity and raising autophagy (Chin 2014).
- Hair-cycle switch: On young mouse skin, α-KG pushed telogen follicles into anagen (Chai 2019). The ATP synthase blocker oligomycin, the TOR blocker rapamycin and activators of AMPK (an enzyme that senses low cellular energy) did the same (Chai 2019), and the autophagy inducer SMER28 also worked (Chai 2019; co-authors are inventors on patent application US20230144845A1).
- Competing explanations: Hair-follicle stem cells need TOR signaling and working mitochondria to activate, so only mild inhibition may help (Chai 2019). In cultured cells, α-KG esters reduced starvation-induced autophagy (Baracco 2019); the authors concluded α-KG does not directly inhibit respiration (Baracco 2019).
- Other routes: AKG is a cofactor for TET enzymes (which remove DNA methyl marks and switch genes on) and histone demethylases (which do the same on DNA-packaging proteins) (Lifespan.io summary), and it activated Wnt signaling (a key hair-growth pathway) in rabbit dermal papilla cells (the follicle’s signaling hub) (Wang 2025).
- Pharmacology: In pigs, AKG is absorbed mainly in the upper small intestine (Dabek 2005); its blood half-life is under 5 minutes, probably from rapid gut and liver metabolism (Dabek 2005). As a normal metabolite it occurs in all tissues, acts on many enzymes, not one target, and has no described cytochrome P450 (drug-metabolizing enzyme) pathway.
Historical Context & Evolution
α-KG was identified as a citric acid cycle intermediate in 1937 (Lifespan.io summary). Its original medical uses were nutritional and renal: mainly French groups gave ornithine α-ketoglutarate (OKG) to burn patients from the 1980s, according to a systematic review (Niederegger 2026), and calcium ketoglutarate was tested as a phosphate binder (a drug that traps dietary phosphate) in dialysis (Bro 1998). Athletes adopted AKG salts for muscle and endurance claims (Lifespan.io summary).
Interest in health optimization followed a 2014 report that α-KG extended worm lifespan through ATP synthase and TOR (Chin 2014). The same UCLA group asked whether that autophagy pathway could restart hair growth, posting a preprint in 2018 (Chai 2018) and publishing in 2019 (Chai 2019); its members are inventors on a University of California hair-growth patent application (US20230144845A1). In 2020 a Buck Institute team reported that dietary Ca-AKG reduced frailty in aging mice, including fur-color loss and poor coat condition in females (Asadi Shahmirzadi 2020); several authors held shares in Ponce de Leon Health (Asadi Shahmirzadi 2020), maker of the Ca-AKG product Rejuvant (Demidenko 2021; co-author Brian Kennedy consults for and sits on the board of Ponce de Leon Health). A 2025 rabbit feeding study reported more hair follicles (Wang 2025).
What changed is the framing, from sports metabolite to candidate longevity and hair agent, driven by animal data from groups with commercial ties; no human hair study has yet tested whether these findings carry over to people.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no controlled human trial from any research group has measured hair counts, hair density or hair-cycle outcomes with ketoglutaric acid given on its own.
Medium 🟩 🟩
No benefit reaches Medium: the only human data touching hair are a retrospective, uncontrolled survey of Rejuvant users that recorded hair status without reporting any change in it (Demidenko 2021; co-author Brian Kennedy consults for and sits on the board of Rejuvant’s maker) and a hair-transplant trial in which ketoglutarate was one ingredient of a graft-storage solution, which is indirect (Zhou 2023).
Low 🟩
Burn Recovery and Wound Healing ⚠️ Conflicted ⭕️ Not Central to Hair Regrowth
OKG improved nitrogen balance and wound closure after burns in a systematic review (Niederegger 2026). An umbrella review found no significant effect on burn clinical outcomes (Naeini 2024). Evidence is indirect: a different salt, in critically ill patients. This bears on injury recovery, not hair. Net: uncertain.
Magnitude: Pooled trials showed no significant change in hospital stay with OKG versus control (mean difference −4.21 days, 95% CI (confidence interval, the range likely to contain the true value) −18.8 to 10.4) (Naeini 2024); the systematic review (Niederegger 2026) reports only direction for nitrogen retention and wound closure.
Hair-Transplant Graft Preservation
In a randomized trial of 240 hair-transplant patients, grafts stored in a solution containing ketoglutarate, histidine, tryptophan, adenosine triphosphate and deferoxamine shed less and regrew sooner than grafts in plain salt solution (Zhou 2023). Evidence is indirect: ketoglutarate was one ingredient of a graft-storage solution.
Magnitude: Postsurgical shedding occurred in 73.81% of patients with the ketoglutarate-containing solution versus 95% with Ringer’s (plain salt) solution when 3,000 or more grafts were transplanted (Zhou 2023); final graft survival did not differ between groups (Zhou 2023).
Speculative 🟨
Hair-Cycle Activation and Regrowth ⚠️ Conflicted
Topical α-KG triggered anagen and regrowth in young mice (Chai 2019); dietary AKG raised follicle density in rabbits (Wang 2025). Treated old mice seemed to regrow slightly less (unquantified) (Chai 2018). Net: young-animal signal only.
Preservation of Hair Pigmentation ⭕️ Not Central to Hair Regrowth
Dietary Ca-AKG from middle age reduced fur-color loss (Asadi Shahmirzadi 2020) and increased hair-bulb melanocytes (pigment cells) in female mice (Asadi Shahmirzadi 2020). Animal data only; this bears on hair greying, not regrowth.
Benefit-Modifying Factors
- Genetic polymorphisms: No gene variant has been tested for AKG response. Pattern hair loss is driven by follicle sensitivity to androgens (male-type hormones), a pathway AKG is not known to target, so genetically androgen-sensitive loss may respond less.
- Baseline biomarker levels: A Buck Institute release, whose study authors held Ponce de Leon Health shares, states plasma AKG can fall up to 10-fold with age (Buck Institute release); whether low baseline predicts hair response is untested.
- Sex: Ca-AKG reduced fur-color loss and poor coat condition in female, not male, mice (Asadi Shahmirzadi 2020); topical α-KG stimulated regrowth in both sexes of young mice (Chai 2019).
- Pre-existing conditions: Mouse data model restarting resting follicles; relevance to androgenetic alopecia (pattern hair loss), alopecia areata (immune-driven patchy loss) or telogen effluvium (stress-related shedding) is untested, and genetic data link higher AKG to alopecia areata (Lei 2025).
- Age: Topical α-KG worked in young mice but seemed to slightly reduce regrowth in old mice in the study’s preprint (Chai 2018), whereas oral α-ketobutyrate (a related keto acid) improved coats of aged mice (Chai 2019).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: adverse-event data for ketoglutaric acid come from single small human trials, none replicated by a second independent research group or conducted in people using it for hair.
Medium 🟥 🟥
Gastrointestinal Intolerance
In a randomized crossover trial in dialysis patients, 5 of 17 taking calcium ketoglutarate as a phosphate binder withdrew within 1–2 weeks with loss of appetite, vomiting, diarrhea or general unease (Bro 1998). All five had prior digestive complaints (Bro 1998), and four had used acid-suppressing drugs (Bro 1998). The gap: same compound, but at phosphate-binding doses in kidney failure rather than 1 g/day supplement use in healthy adults.
Magnitude: 5 of 17 (29%) withdrew for intolerance on calcium ketoglutarate (Bro 1998); the abstract reports no intolerance rate for the calcium carbonate comparison arm, whose participants had all tolerated it before enrolment (Bro 1998).
Low 🟥
Alopecia Areata Susceptibility
A Mendelian randomization study (using inherited gene variants as a natural experiment) linked genetically higher blood AKG to higher alopecia areata risk (Lei 2025). Evidence is indirect: lifelong inborn levels, not supplementation. Net: an unconfirmed signal.
Magnitude: Odds ratio (OR, the relative odds of the condition) 1.57 (95% CI 1.20–2.05) per unit of genetically predicted AKG (Lei 2025); this is a genetic estimate (no control group), and no absolute rates are reported.
Palpitations and Fainting with Arginine-AKG Products
Three young men attended emergency departments with palpitations (a racing or pounding heartbeat), dizziness or fainting after arginine alpha-ketoglutarate “nitric oxide” sports supplements (Prosser 2009); two were admitted (Prosser 2009). Evidence is indirect: a different salt in multi-ingredient products, with arginine-driven blood-vessel widening the proposed cause.
Magnitude: Not quantified in available studies. Only three case reports exist, with no control group and no count of exposed users (Prosser 2009).
Speculative 🟨
Tumor Growth Modulation ⚠️ Conflicted
Dietary Ca-AKG accompanied larger lung tumors in male mice, smaller in females (Alcaraz 2026); dietary AKG slowed B-cell lymphoma (a blood cancer) in mice (Jaafar 2025). Net: direction varies by tumor and sex.
Scalp Irritation from Topical Products
Applied every other day for 39 days, α-KG caused no visible skin irritation in mice (Chai 2019). Human scalp tolerance of acidic AKG serums is untested; the concern is mechanistic only.
Risk-Modifying Factors
- Genetic polymorphisms: Inherited variants that raise blood AKG were linked to alopecia areata risk (Lei 2025); no variant affecting how the body handles supplemental AKG is known.
- Baseline biomarker levels: Ca-AKG is a calcium salt, so serum calcium matters; calcium ketoglutarate produced lower ionized calcium (the free, active fraction of blood calcium) than calcium carbonate in dialysis patients (Bro 1998), but it still adds to total calcium intake.
- Sex: Ca-AKG’s association with lung tumor size went in opposite directions by sex in mice, unfavorable in males (Alcaraz 2026); no sex difference in human adverse events has been reported.
- Pre-existing conditions: All intolerance cases in dialysis patients had prior digestive symptoms (Bro 1998); active cancer and autoimmune hair loss are untested settings with animal or genetic warning signals.
- Age: ABLE, using Ponce de Leon Health’s Ca-AKG with co-author Kennedy on its board, enrolls adults aged 40–60 (Sandalova 2023), so tolerance in people over 65, who more often take interacting drugs, is less documented.
Key Interactions & Contraindications
Documented interactions:
- Quinolone antibiotics (ciprofloxacin – Cipro): Calcium-containing products reduce absorption, risking treatment failure; the label says to take Cipro at least 2 hours before or 6 hours after them (Cipro label). This applies to Ca-AKG.
- Levothyroxine (Synthroid): Calcium carbonate binds levothyroxine and can cause hypothyroidism (underactive thyroid); the label says to separate them by at least 4 hours (Synthroid label). Ca-AKG is a different calcium salt; the same spacing applies.
- Tetracycline antibiotics (doxycycline – Doryx MPC): Calcium-containing antacids impair tetracycline absorption, risking treatment failure (Doryx MPC label). Ca-AKG supplies calcium; doses are separated.
- Bisphosphonates (bone-loss drugs such as alendronate – Fosamax): Calcium interferes with alendronate absorption, weakening its bone effect; the label says to wait at least 30 minutes after Fosamax before other oral products (Fosamax label). This applies to Ca-AKG.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Acid-suppressing drugs (cimetidine, omeprazole): Inferred from shared digestive vulnerability: four of five dialysis participants who stopped calcium ketoglutarate for intolerance had used these drugs before enrolment (Bro 1998); consequence: possibly higher intolerance risk. A low starting dose is the usual mitigation.
- Antacids (aluminum or magnesium hydroxide): Inferred from pig data showing better AKG absorption at low pH (Dabek 2005); raising pH may reduce uptake. Spacing doses 2 hours apart avoids the overlap.
- Iron supplements (ferrous sulfate): Ferrous iron raised AKG absorption in pigs (Dabek 2005); consequence: higher AKG exposure when taken together, with no shown effect on iron uptake. Separating the doses avoids the overlap.
- Calcium and vitamin D supplements: Additive calcium intake from Ca-AKG; consequence: excess calcium load. Ca-AKG’s calcium counts toward the daily total.
- Other AKG salts (arginine-AKG, ornithine-AKG, creatine-AKG): Additive AKG dose from stacked products, plus arginine’s own effects with arginine-AKG; consequence: unintended higher intake. Reading all product labels prevents duplication.
- mTOR (mammalian TOR) inhibitors and AMPK activators (rapamycin – sirolimus, metformin): Rapamycin and metformin each stimulated hair growth via autophagy in mice (Chai 2019); combined use may add autophagy induction, with unknown effect on follicles. Never tested together.
- HIF (hypoxia-inducible factor, an oxygen-sensing switch) prolyl hydroxylase (the enzyme that tags HIF for breakdown) inhibitors (daprodustat – Jesduvroq): AKG supports prolyl hydroxylase-2 activity (Agarwal 2023), the enzyme these anemia drugs block; high AKG could blunt their effect, detectable by hemoglobin checks.
- Minoxidil, finasteride, microneedling: Different mechanisms (minoxidil opens potassium channels; finasteride blocks conversion of testosterone to dihydrotestosterone); no interaction expected, and the combined effect on hair is unknown.
Populations who should avoid Ketoglutaric Acid:
- Pregnancy and breastfeeding: Inferred from AKG’s role as a cofactor for DNA- and histone-demethylating enzymes that steer development (Lifespan.io summary); no human data.
- Active cancer, especially lung adenocarcinoma (the most common lung cancer type) in men: Inferred from mouse data showing larger tumors in males (Alcaraz 2026); no human data.
- Chronic digestive symptoms or acid-suppressant users: Human evidence: all intolerance cases in a dialysis trial occurred in this group (Bro 1998).
- Hypercalcemia (serum calcium above the reference range), for Ca-AKG: Inferred from additive calcium load; no human data.
- Alopecia areata, personal history: Inferred from a genetic association between higher AKG and disease risk (Lei 2025); no supplementation data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Low starting dose: Protocols typically begin at 0.5 g/day of Ca-AKG with food, rising to 1 g/day after 1–2 weeks if tolerated; mitigates the gastrointestinal intolerance seen in 29% of dialysis patients (Bro 1998).
- Dose separation: Cipro is taken at least 2 hours before or 6 hours after calcium products (Cipro label) and levothyroxine 4 hours apart (Synthroid label); prevents reduced drug absorption.
- Calcium accounting: Ca-AKG’s calcium is counted toward daily intake, with serum calcium checked at baseline and 3 months and use stopped above the reference range; prevents excess calcium load.
- Patch test for topical serums: A 48-hour test on a small skin area before scalp use prevents widespread scalp irritation.
- Cancer status: Use is avoided during active cancer, with age-appropriate cancer screening kept current; addresses the mouse tumor-growth signal (Alcaraz 2026).
- Stop on new patchy hair loss: Use is stopped and a dermatologist’s assessment sought if round bald patches appear; addresses the alopecia areata genetic signal (Lei 2025).
Therapeutic Protocol
Other parameters without a citation (timing, titration, duration) reflect common practice; each dose is cited to its source.
- No hair-specific protocol: No human trial has tested AKG alone for hair; the regimens below come from human longevity, bone and kidney trials and from mouse hair studies.
- Oral Ca-AKG, 1 g/day: Sustained-release dose in the ABLE trial (Sandalova 2023) and in Rejuvant, combined with vitamin A for men or vitamin D for women (Demidenko 2021); popularized by Brian Kennedy and Buck Institute researchers.
- Oral Ca-AKG, 2 g/day split: Two 0.5 g tablets twice daily for 12 weeks in a completed placebo-controlled trial sponsored by the company Shenzhen Hygieia Biotech (NCT07114536).
- Oral AKG, 6 g/day: Given with 1.68 g/day calcium for 6 months to postmenopausal women in a randomized trial (Filip 2007).
- Topical α-KG (research only): 32 mM in a lecithin-based gel every other day on shaved resting-phase mouse skin (Chai 2019); popularized by Jing Huang’s UCLA group. No human concentration has been tested.
- Time of day: No study compared timing; oral doses are commonly taken with meals to limit digestive upset.
- Half-life: AKG leaves the blood within minutes, with a half-life under 5 minutes in pigs (Dabek 2005), the rationale for sustained-release products.
- Single or split dose: ABLE gives 1 g/day sustained-release Ca-AKG without stated timing (Sandalova 2023); the 2 g/day regimen was split twice daily (NCT07114536); in volunteers, split doses with water raised bioavailability (share of a dose reaching blood) (Mittal 2010).
- Genetic polymorphisms: No variant guides AKG dosing; inherited higher AKG has been linked to alopecia areata (Lei 2025).
- Sex: Rejuvant uses sex-specific vitamin pairings (Demidenko 2021); hair-related mouse benefits of Ca-AKG appeared mainly in females (Asadi Shahmirzadi 2020).
- Age: Topical α-KG seemed less effective in old mice (Chai 2018); the ABLE trial enrolls ages 40–60 (Sandalova 2023).
- Baseline biomarker levels: ABLE selected adults whose DNA methylation age (an epigenetic estimate of biological age) exceeded their calendar age (Sandalova 2023); no hair-relevant baseline marker guides dosing.
- Pre-existing health conditions: Dialysis patients took calcium ketoglutarate under supervision as a phosphate binder (Bro 1998); prior digestive disorders favor a low starting dose.
- Established alternatives: Minoxidil and finasteride have human hair-trial evidence that AKG lacks; AKG has never been tested as an add-on to them.
Discontinuation & Cycling
- Short-term or lifelong: Human Ca-AKG regimens ran 12 weeks (NCT07114536) to 6 months (Sandalova 2023); no data support lifelong use, and no study has tested hair effects over any duration.
- Withdrawal effects: None reported in human trials; AKG is a normal metabolite the body keeps producing.
- Tapering: Not required for safety; hair gained through hair-cycle stimulation might shed after stopping, which no study has examined.
- Cycling: The mouse topical protocol used every-other-day application (Chai 2019); no evidence shows that cycling maintains or improves any effect.
Sourcing and Quality
- Forms: AKG is sold as the free acid, as Ca-AKG (often sustained-release) and as arginine, ornithine and creatine salts; hair research used α-KG on the skin of mice and Ca-AKG or AKG in animal feed.
- Delayed-release Ca-AKG: Sold as “dAKG” or Ca-AKG and typically costing several times plain AKG (ConsumerLab answer).
- Brands: ConsumerLab names ProHealth Longevity, Renue by Science and Rejuvant as Ca-AKG sellers (ConsumerLab answer); Rejuvant’s maker, Ponce de Leon Health (Demidenko 2021), funded the key mouse study (Asadi Shahmirzadi 2020).
- Third-party testing: Quality markers are USP, NSF or ConsumerLab certification, or a certificate of analysis stating AKG content and heavy-metal limits.
- Topical products: FDA does not count topical products as dietary supplements (FDA Q&A on dietary supplements); cosmetics need no FDA approval before sale, and a claim to restore hair growth makes a product a drug (FDA cosmetic-or-drug guidance).
- Calcium content: Ca-AKG supplies calcium; the label’s elemental calcium per serving shows how much it adds to daily intake.
Practical Considerations
- Time to effect: In mice, anagen began within 7 days (Chai 2019), skin darkening was visible by day 12 (Chai 2019) and regrowth was robust by day 39 (Chai 2019); human hair cycles are far longer, and no human time course exists.
- Common pitfalls: Treating mouse data as human proof, confusing AKG with α-ketobutyrate, replacing established hair therapies with AKG, and buying arginine-AKG sports products expecting the effects reported for Ca-AKG.
- Regulatory status: Swallowed AKG is sold in the US as a dietary supplement, while topical serums fall outside that category (FDA Q&A on dietary supplements); a University of California patent application covers hair use (US20230144845A1).
- Cost and access: Widely available without prescription; Ca-AKG costs several times plain AKG (ConsumerLab answer).
Interaction with Foundational Habits
- Sleep: None known (direction: none). No study reports an AKG effect on sleep; the ABLE trial measures sleep quality as a secondary outcome (NCT05706389). Sleep timing need not be adjusted around dosing.
- Nutrition: Indirect. The body produces its own AKG within the citric acid cycle (Lifespan.io summary). Taking oral forms with meals limits digestive upset, and Ca-AKG’s calcium counts toward dietary calcium; no diet is known to change AKG’s effect on hair.
- Exercise: Potentiating (indirect). Adding interval exercise to a low-calorie diet raised blood α-KG more than the diet alone in women with obesity (Ragland 2024); no study has tested whether training changes AKG’s effect on hair.
- Stress management: None documented. AKG has no reported effect on cortisol (the main stress hormone), and stress-related shedding has not been studied with AKG; managing stress remains independent of AKG use.
Monitoring Protocol & Defining Success
Baseline testing before starting includes standardized scalp photographs under fixed lighting, a hair count or phototrichogram (magnified imaging that counts hairs per area) at a marked scalp site, serum calcium for Ca-AKG users, and thyroid-stimulating hormone (TSH, a pituitary signal that rises when thyroid hormone runs low) for people taking levothyroxine.
Ongoing monitoring follows this cadence: repeat photographs and hair counts at 3 and 6 months, then every 6–12 months while use continues; serum calcium at 3 months; and TSH 6–8 weeks after any change in how Ca-AKG is spaced around levothyroxine. Because no human hair trial of AKG alone exists, success is defined against the person’s own baseline at the same scalp site.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Hair density (phototrichogram or standardized hair count) | No established target; track change from own baseline | Expected to change (intended effect) | Same marked site, lighting and hair length each time; evidence of effect is from mice only (Chai 2019) |
| Serum calcium | 8.6–10.3 mg/dL (standard reference range) | Safety check: Ca-AKG adds calcium | Fasting not required; pair with albumin to interpret total calcium |
| TSH (levothyroxine users only) | 0.4–4.0 mIU/L (standard reference range) | Safety check: calcium can reduce levothyroxine absorption | Morning draw; retest 6–8 weeks after changes (Synthroid label) |
| Serum AKG | No established target; track change from own baseline | Expected to change (confirms uptake) | Research laboratories only; measured in the ABLE trial (NCT05706389) |
Qualitative markers:
- Shedding seen in the shower or brush
- Width of the hair part and visible scalp under fixed lighting
- Hair pull test result (number of hairs released by gentle traction)
- Scalp comfort with topical products (itch, redness, stinging)
- Digestive tolerance of oral forms
- Any new round patches of hair loss
Emerging Research
- ABLE trial (NCT05706389): Phase 2, 120 adults aged 40–60, 1 g/day Ca-AKG versus placebo for 6 months; primary endpoint DNA methylation age. Active, not recruiting; primary completion August 2025, no results posted. No hair outcome: a positive result would strengthen the general aging rationale, a null result weaken it.
- Ca-AKG in middle-aged and older adults (NCT07114536): 34 participants, 2 g/day for 12 weeks versus placebo; primary endpoint PhenoAge (a blood-test estimate of biological age). Completed November 2025, no results posted. Its adverse-event data, once released, could confirm or challenge tolerability at 2 g/day.
- AKG and brain aging (NCT07861867): Phase 2, 60 older adults, 1 g/day Ca-AKG versus placebo for 24 weeks; Ponce de Leon Health collaborates; not yet recruiting. A positive or clean safety result would extend tolerability to older adults; a null or adverse result would narrow AKG’s studied population.
- AKG and aortic aneurysm (NCT04723888): 300 patients, recruiting, completion expected December 2026, primary endpoint aortic diameter. Positive or neutral safety findings would add long-term human tolerance data; harm would raise the risk grades in this review.
- AKG in heart bypass surgery (NCT07031128): Phase 4, 250 adults aged 50+ having bypass surgery, 1 g/day AKG versus placebo; primary endpoint postoperative inflammation with organ dysfunction. Recruiting, completion expected December 2026. A positive result would add tolerance data in older adults; a null or harmful one would weaken the safety case.
- Human topical hair trial: No registered trial tests α-KG on the human scalp; a controlled trial in pattern hair loss would be the first direct test, building on the mouse work and patent filings (Chai 2019; US20230144845A1).
- Follicle signaling: Rabbit and dermal papilla data on Wnt activation (Wang 2025) could strengthen the case if replicated in human follicle cultures, or weaken it if they prove species-specific.
- Safety signals to replicate: The alopecia areata genetic signal (Lei 2025) and sex-dependent tumor effects in mice (Alcaraz 2026) could weaken the case if confirmed, or be set aside if not reproduced.
Conclusion
Ketoglutaric acid is a natural energy-cycle compound sold mainly as a calcium salt and promoted for healthy aging; its hair claim grows out of that aging research rather than from hair-loss studies in people.
Nearly every result that supports hair regrowth comes from animals; the one human trial stored transplanted hair in a solution that contains it among other ingredients. Applied to the skin, it switched resting hair roots in young mice into growth; added to feed, it raised hair-root numbers in rabbits and kept fur color in older female mice. The same research group noticed a slight opposite effect on old mouse skin, and no study has measured hair in people taking it.
The human safety record is short and comes from small trials in kidney, bone and burn care. Digestive upset, seen in kidney patients with existing stomach problems, is the clearest side effect. A genetic study ties naturally higher levels to immune-driven patchy hair loss, and mouse work shows tumor effects that differ by sex. The calcium form can reduce the uptake of some thyroid and antibiotic medicines.
Much of the leading research comes from scientists who hold shares in a company selling the calcium form or who are named on hair-growth patent filings, and independent confirmation is thin. For people already following proven hair routines and open to experimental additions, the compound remains an untested idea for hair rather than an established treatment, with low but incompletely charted risk.